Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | ERBB3 positive |
| Therapy | Lumretuzumab |
| Indication/Tumor Type | triple-receptor negative breast cancer |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| ERBB3 positive | triple-receptor negative breast cancer | sensitive | Lumretuzumab | Phase I | Actionable | In a Phase I trial, Lumretuzumab treatment resulted in tumor shrinkage in a patient with Erbb3 (Her3)-expressing triple-receptor negative breast cancer (PMID: 26463709). | 26463709 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (26463709) | First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid Tumors. | Full reference... |